UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August~~September 1527, 2023 ~~(August 14, 2023)~~

FUSE MEDICAL, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware 000-10093 59-1224913

Delaware	000-10093	59-1224913
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1565 North Central Expressway Suite 220 Richardson, Texas		75080
(Address of Principal Executive Offices)		(Zip Code)

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

1565 North Central Expressway Suite 220 Richardson, Texas 75080

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (469) 862-3030

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		FZMD		OTCPink

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 23.0201 Notice ~~Results~~ of ~~Operations~~Delisting ~~and~~or ~~Financial~~Failure ~~Condition~~to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

~~The~~On ~~information~~September in27, ~~Item~~2023, 2Fuse Medical, Inc.02 of(the ~~this~~“Company”) ~~report~~issued ~~(including~~a ~~Exhibit~~press ~~99.1)~~release ~~shall~~announcing ~~not~~that bea ~~deemed~~Form “15 has been filed” ~~for~~with ~~purposes~~the ofSecurities ~~Section~~and 18Exchange ofCommission (SEC) to voluntarily deregister its common stock and suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),. orThe ~~otherwise~~full ~~subject~~text toof the ~~liabilities~~press ofrelease ~~that~~issued ~~section, nor shall it be deemed incorporated by reference~~ in ~~any~~connection ~~filing~~with ~~under~~ the ~~Securities~~announcement ~~Act~~is offurnished ~~1933,~~ as ~~amended,~~Exhibit or99.1 ~~the~~to ~~Exchange~~this ~~Act,~~Current ~~except~~Report ason ~~expressly~~Form ~~provided~~8-K byand ~~specific~~incorporated ~~reference~~herein inby ~~such a filing~~reference.

On August 15, 2023, Fuse Medical, Inc. (the “Company”) issued a press release reporting the financial results of the Company for the second quarter ending June 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1*		Press Release, dated ~~August~~September 1527, 2023 Fuse Medical, Inc. Announces Decision to Voluntarily Terminate Registration of Its Common Stock with the SEC
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Fuse Medical, Inc.
Date: August 15, 2023	By:	/s/ Lawrence Yellin
Date: September 27, 2023	By:	/s/ Lawrence Yellin
		Lawrence Yellin
		Chief Financial Officer and Director

Filing Compare · Fuse Medical, Inc.